JSPCCS-AHA Joint Session（II-AHAJS）
先天性心疾患における新規心不全治療薬の夜明け/Dawn of new drugs for heart failure in patients with congenital heart disease
第一部「先天性心疾患における新規心不全治療薬の国内使用経験」
第二部「先天性心疾患における新規心不全治療薬の日米使用経験」

[II-AHAJS-07] Japanese nationwide survey for actual usage of new heart failuere drugs in patients with congenital heart disease

^○Jun Muneuchi¹, Hideaki Senzaki², Naomi Nakagawa³, Yoshihide Mitani⁴, Hiroyuki Yamagishi⁵ (1.Kyushu Hospital, Japan Community Healthcare Organization, 2.Nihon Institute of Medical Science, 3.Hiroshima City Hospital, 4.Mie University, 5.Keio University)

Clinical evidences have been accumulated on new heart failure drugs including a sodium-glucose cotransporter inhibitor, ivabradine, an angiotensin-converting enzyme/neprilysin inhibitor, and a soluble guanylate stimulator, for adults with heart failure; however, it remains unclear whether these new heart failure drugs are feasible and effective among patients with congenital heart disease. Thus, we performed the nationwide survey for actual usage of these drugs in patients with congenital heart disease in Japan. We are pleased to show you the result at this joint session between the American Heart Association and the Japanese Society of Pediatric Cardiology and Cardiovascular Surgery. We also do hope that this survey will serve as a stepping stone to international collaboration and clinical trials for patients, both adults and children, with congenital heart disease.